BMBernhard Maisch

Bernhard Maisch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bernhard Maisch has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic variability in the bag3 gene (BCL2-associated athanogene 3) in patients with dilated cardiomyopathy

    by V. Ruppert, C. Onda-Ono, T. Meyer, A. Richter, B. Maisch, S. Pankuweit, German Competence Network Of Heart Failure

    Dilated cardiomyopathy (DCM) is a disease of the heart muscle characterized by ventricular dilation and impaired systolic function. In a genome-wide association study within the framework of the European Heart Failure Project, DCM-associated single nucleotide polymorphisms (SNPs) with a p-value C, p.C151R) in the sequence of the BCL2-associated athanogene 3 (BAG3) gene on chromosome 10q26. Mutations in the bag3 gene have been reported in patients with serious amyasthenia. BAG3 inhibits the chaperone activity of HSP70 and is involved in the turn-over of filamin. Mutations in the bag3 gene suppressed the degradation of filamin and have been found in patients with serious muscle damage. The present study describes a systematic approach in the search for disease-associated mutations in the coding regions of the bag3 gene in patients with DCM. Methods: By means of physical examination, ECG, echocardiography and cardiac catheterization 257 unrelated patients with clinically diagnosed DCM in the German Competence Network of Heart Failure (KNHI) were recorded. Mutation screening was performed by PCR, denaturing gradient gel electrophoresis (DGGE) and direct sequencing. The pathogenicity of identified mutations was estimated by Mutation taster and PolyPhen2. Results: In addition to the known SNPs rs196294 (c.910-21A>C), rs3858339 (c.1002T>G, p.P334P) and rs3858340 (c.1220C>T, p.P407L), a heterozygous missense mutation in the bag3 gene was identified in an index patient diagnosed with DCM. The mutation affected codon 206 (p.I206V) in exon 3 and resulted in a substitution of a valine residue for isoleucine in a highly conserved protein domain. The online programs Mutation taster and PolyPhen2 classified the mutation as a putative pathological amino acid exchange. However, the point mutation was also detected in one of 334 controls. Conclusions: In a cohort study of 250 patients, a missense mutation in the bag3 gene located in a highly conserved region of the molecule was detected in a patient with sporadic DCM. The identified heterozygous bag3 mutation may have functional significance in the pathogenesis of DCM, since it is localized close to the known P209L mutation, which has been reported as a cause of myofibrillar disease. Patients with the P209L mutation regularly develop a cardiomyopathy in the course of the disease.

  • Assessment of increased left ventricular wall stress with the volume-based wall stress index – prediction of left ventricular hypertrophy and late gadolinium enhancement in dilative heart failure

    by P Alter, H Rupp, Jh Figiel, Mb Rominger, B Maisch

    Introduction: Increased left ventricular (LV) wall stress is an unfavourable prognostic determinant in dilative cardiomyopathy. Besides LV hypertrophy, occurrence of late gadolinium enhancement (LGE) as assessed by cardiac magnetic resonance (CMR) imaging was associated with an adverse outcome. We hypothesized, therefore, that increased LV wall stress is involved in the development of LV hypertrophy and is associated with LGE. Methods: LV mass, LV enddiastolic (LVEDV) and endsystolic volume (LVESV) was determined by CMR. Presence or absence of LGE was assessed in 300 patients. Based on a thick-walled sphere model, we introduced a myocardial and cavity volume-based wall stress index. In another group of 71 patients, the development of LV mass was assessed during follow-up. Results: LV enddiastolic and endsystolic wall stress, LV volumes and mass (P4 kPa developed greater LV hypertrophy during follow-up (P4 Conclusions: Use of the volume-based wall stress index allows to calculate LV wall stress based on CMR measurements of LV volume and mass. As shown, increased LV wall stress leads to LV hypertrophy. It is a novel finding that increased wall stress is associated with the occurrence of LGE in dilative cardiomyopathy. Since both features are linked with worse outcome, it can be inferred that increased LV wall stress is the underlying unfavourable determinant and other parameters are surrogate markers only. Increased LV wall stress leads to a vicious circle of heart failure progression with on-going dilatation and can account for the increased risk of sudden cardiac death involving wall stress-sensitive cation channels. Since we have already established the measurement of wall stress in heart failure as diagnostic routine procedure, the volume-based wall stress index could be used whenever invasive pressure data are not available.


  • Von Leitlinien zu Behandlungspfaden

    by Bernhard Maisch, Rolf Dörr


  • Akute Herzinsuffizienz

    by Bernhard Maisch

  • Open Access

    Recurrent pericarditis: mysterious or not so mysterious?

    by Bernhard Maisch

    This editorial refers to ‘Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis’† by G. Artom et al., on page 723


  • Bacterial Pericarditis

    by Sabine Pankuweit, Arsen D. Ristić, Petar M. Seferović, Bernhard Maisch

    Bacterial pericarditis occurs by direct infection during trauma, thoracic surgery, or catheter drainage, by spread from an intrathoracic, myocardial, or subdiaphragmatic focus, and by hematogenous...


  • Komplizierter Verlauf eines Churg-Strauss-Syndroms mit eosinophiler Perimyokarditis und Perikard-Tamponade

    by S. Lamparter, S. Pankuweit, S. Kölsch, B. Maisch

    Anamnese: Ein 30-jähriger Patient litt seit etwa 2 Jahren an trockenem Husten und zunehmender Dyspnoe; seit 8 Wochen klagte er über linksthorakale Schmerzen und einen Gewichtsverlust von 15 kg. Untersuchungen: Die körperliche Untersuchung ergab eine deutliche Atemabhängigkeit der Blutdruck-Amplitude sowie Zeichen der oberen Einflussstauung. Radiologisch bestand eine Kardiomegalie ohne pulmonale Infiltrate. Als Ursache der Kardiomegalie ergab sich ein tamponierender Perikarderguss, welcher abpunktiert wurde. Im Rahmen der Perikardioskopie wurden sowohl perikardiale als auch epimyokardiale Biopsien entnommen. Neben erhöhten myokardialen Nekrosemarkern fand sich eine Hypereosinophilie ohne Hinweis auf eine Parasitose bzw. eine myeloproliferative Erkrankung. Der histologische Befund der Epimyokardbiopsie ergab eine floride eosinophile Myokarditis. Diagnose, Therapie und Verlauf: Es wurde die Diagnose eines Churg-Strauss-Syndroms mit kardialer Beteiligung gestellt. Nach intraperikardialer Gabe von 500 mg Triamcinolon folgte eine systemische Kortikosteroidtherapie, worunter sich die Eosinophilie zurückbildete. Ein Perikardergussrezidiv trat im Verlauf von 18 Monaten nicht mehr auf. Allerdings kam es bei dem Versuch, die Steroiddosis auf unter 15 mg Prednisolonäquivalent pro Tag zu reduzieren, zu einem Anstieg der eosinophilen Granulozyten und zu einer Zunahme der Asthma-Anfälle. Eine angeratene Therapie mit Cyclophosphamid lehnt der Patient bislang ab. Folgerung: Bei Verdacht auf ein Churg-Strauss-Syndrom mit kardialer Beteiligung sollte zum Ausschluss einer viralen Myokarditis vor Einleitung einer immunsuppressiven Therapie mit Kortikosteroiden eine invasive Diagnostik einschließlich Myokardbiopsie erwogen werden. History: A 30-year-old patient suffered from a dry cough and increasing dyspnea since two years; he further complained about non radiating chest pain and weight loss of 15 kg in the past 8 weeks. Examinations: Physical examination revealed pulsus paradoxus and distended neck veins. On chest x-ray, signs of cardiomegaly without infiltrations were found. Echocardiographic studies demonstrated a large pericardial effusion with signs of pericardial tamponade. Pericardiocentesis and pericardioscopy was performed and pericardial as well as epimyocardial biopsy samples were taken. Serum studies revealed increased markers of myocardial infarction and hypereosinophilia without clinical evidence of parasitic, myeloproliferative, or neoplastic diseases. Diagnosis of acute eosinophilic myocarditis was established in the epimyocardial biopsy samples. Diagnosis, treatment and course: Based on the clinicopathologic findings, we diagnosed Churg Strauss syndrome with cardiac involvement. We instillated 500 mg triamcinolone intra-pericardially and initiated systemic treatment with corticosteroids which resulted in normalization of the blood eosinophil count. During a follow up of 18 months, no recurrence of pericardial effusion was detected. However, while trying to reduce the steroids below 15 mg prednisolone equivalent per day, eosinophil numbers raised and wheezing increased. We suggested an immunosuppresive therapy including cyclophosphamide according to the Fauci protocol, which was denied by the patient due to potential adverse side effects. Conclusion: We suggest a detailed invasive strategy including endomyocardial biopsy to rule out viral myocarditis before immunosuppressive therapy with steroids is initiated in patients with suspected cardiac involvement in Churg Strauss syndrome.